Click here to view online. Add this email to your safelist.
Novel genetic targets for fatty liver disease
5 July 2023
We have been collaborating with Prof Stefano Romeo for around five years to identify and validate novel therapeutic targets for NASH, a chronic liver disease which can have serious, life-threatening consequences.
This joint article and accompanying video shares the process and results from research that identified and validated PSD3, a new genetic target that has been shown to be associated with fatty liver disease.1
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
